Half the world faced an extra month of extreme heat due to climate change: study
Half the global population endured an additional month of extreme heat over the past year because of manmade climate change, a new study found Friday.
The findings underscore how the continued burning of fossil fuels is harming health and well-being on every continent, with the effects especially under-recognized in developing countries, the authors said.
"With every barrel of oil burned, every tonne of carbon dioxide released, and every fraction of a degree of warming, heat waves will affect more people," said Friederike Otto, a climate scientist at Imperial College London and co-author of the report.
The analysis -- conducted by scientists at World Weather Attribution, Climate Central, and the Red Cross Red Crescent Climate Centre -- was released ahead of global Heat Action Day on June 2, which this year spotlights the dangers of heat exhaustion and heat stroke.
To assess the influence of global warming, researchers analyzed the period from May 1, 2024 to May 1, 2025.
They defined "extreme heat days" as those hotter than 90 percent of temperatures recorded at a given location between 1991 and 2020.
Using a peer-reviewed modeling approach, they then compared the number of such days to a simulated world without human-caused warming.
The results were stark: roughly four billion people -- 49 percent of the global population -- experienced at least 30 more days of extreme heat than they would have otherwise.
The team identified 67 extreme heat events during the year and found the fingerprint of climate change on all of them.
The Caribbean island of Aruba was the worst affected, recording 187 extreme heat days -- 45 more than expected in a world without climate change.
The study follows a year of unprecedented global temperatures. 2024 was the hottest year on record, surpassing 2023, while January 2025 marked the hottest January ever.
On a five-year average, global temperatures are now 1.3 degrees Celsius above pre-industrial levels -- and in 2024 alone, they exceeded 1.5C, the symbolic ceiling set by the Paris climate accord.
The report also highlights a critical lack of data on heat-related health impacts in lower-income regions.
While Europe recorded more than 61,000 heat-related deaths in the summer of 2022, comparable figures are sparse elsewhere, with many heat-related fatalities misattributed to underlying conditions such as heart or lung disease.
The authors emphasized the need for early warning systems, public education, and heat action plans tailored to cities.
Better building design -- including shading and ventilation -- and behavioral adjustments like avoiding strenuous activity during peak heat are also essential.
Still, adaptation alone will not be enough. The only way to halt the rising severity and frequency of extreme heat, the authors warned, is to rapidly phase out fossil fuels.
ia/sla
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Women on blockbuster weight loss drugs warned to use effective contraception
Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.
Yahoo
9 hours ago
- Yahoo
Women on blockbuster weight loss drugs warned to use effective contraception
Pregnant women should not take weight loss drugs, the UK's medicines regulator warned amid concerns that people are using the so-called 'skinny jabs' in unsafe ways. The UK Medicines and Healthcare products Regulatory Agency (MHRA) also said women should not take weight loss drugs if they are breastfeeding or trying to get pregnant, because there isn't enough safety data to know whether the medicine could affect their baby. 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible,' the agency said. Meanwhile, all women taking the jabs should ensure they are using a form of contraception that works, the MHRA said. Related Weight-loss drugs like Wegovy could help serious liver condition that has no cure-all treatment One of the drugs, Mounjaro, may make birth control pills less effective, so the agency says women taking the jab should also use a non-oral form of contraception, like an implant or intrauterine device (IUD). 'Obesity reduces fertility in women. So, women with obesity taking GLP-1 drugs are more likely to get pregnant than before they lost weight,' Dr Channa Jayasena, a reproductive endocrinology researcher at Imperial College London, said in a statement. 'Women are advised to do all they can to prevent pregnancy while taking [these] drugs,' Jayasena added. Related France won't pay for weight loss drug Wegovy. What about other European countries? In the UK, women already receive these warnings when they get their prescriptions for the blockbuster jabs, which include Ozempic, Wegovy, Saxenda, and Victoza as well as Mounjaro. The drugs, known as GLP-1 receptor agonists, work by mimicking hormones that help regulate appetites and make people feel full for longer. They have been approved to treat type 2 diabetes and obesity. Related Why are 1 in 10 French women still smoking during pregnancy despite the health risks? But the MHRA issued the reminder Thursday due to concerns that the drugs' growing popularity means women are buying them illegally online or at beauty salons, without seeing a doctor. 'Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments,' Dr Alison Cave, MHRA's chief safety officer, said in a statement. 'They are not a quick fix to lose weight and have not been assessed to be safe when used in this way,' she added.


Medscape
9 hours ago
- Medscape
Diabetes Status May Not Affect Outcomes of Preventive PCI
The PREVENT trial found preventive percutaneous coronary intervention (PCI) combined with optimal medical therapy was more effective than medical therapy alone in reducing major adverse cardiac events in patients with non–flow-limiting vulnerable plaques. The new analysis found patients with non–flow-limiting vulnerable plaques had similar 2-year cardiac outcomes regardless of diabetes status, but those who received preventive PCI combined with optimal medical therapy had lower rates of cardiac events than those who received medical therapy alone. METHODOLOGY: The post hoc analysis of the PREVENT data compared the clinical outcomes of preventive PCI plus optimal medical therapy and medical therapy alone in patients with (n = 490) or without (n = 1116) diabetes. Plaques were defined as non–flow-limiting when the fractional flow reserve was > 0.80; vulnerable plaques were identified using intracoronary imaging. The primary endpoint was a composite of cardiac death, target vessel myocardial infarction, ischemia-driven target vessel revascularization, or hospitalization for unstable or progressive angina at 2 years after randomization; the median follow-up duration was 4.3 years. TAKEAWAY: At 2 years, the incidence of the composite primary endpoint was not significantly different between patients with diabetes and those without the condition (1.8% and 1.9%, respectively; P = .956). = .956). The composite primary endpoint occurred less frequently with preventive PCI than with optimal medical therapy alone for both patients with diabetes (0% vs 3.7%; log-rank P = .003) and those without diabetes (0.5% vs 3.2%; log-rank P < .001). = .003) and those without diabetes (0.5% vs 3.2%; log-rank < .001). The reduced incidence of the primary endpoint with preventive PCI was mainly driven by reduced rates of ischemia-driven target vessel revascularization and hospitalizations for unstable or progressive angina in both patients with diabetes and those without the disorder. IN PRACTICE: 'These findings support that preventive PCI…irrespective of diabetes status, in patients with non–flow-limiting vulnerable coronary plaques,' the researchers wrote. Vulnerable plaques 'may be guilty by association but may not be the sole culprit behind residual cardiovascular risk,' wrote Diana A. Gorog, MD, PhD, of Imperial College London, London, England, in an editorial accompanying the journal article. Such plaques 'may be just one marker of a vulnerable patient, but not the only determinant of risk. Perhaps we need to find better ways of identifying the vulnerable patient, rather than focusing solely on vulnerable plaques,' Gorog added. SOURCE: This study was led by Min Chul Kim of Chonnam National University Hospital in Gwangju, South Korea. It was originally presented at American College of Cardiology (ACC) Scientific Session 2024 and was published online on May 29, 2025, in European Heart Journal . LIMITATIONS: The clinical outcomes were exploratory as the study was powered only for the composite primary endpoint, with event rates lower than anticipated. The researchers did not differentiate between type 1 and type 2 diabetes, which might have limited the generalizability of the findings. Intravascular imaging at follow-up was not performed routinely. DISCLOSURES: This study was funded by the CardioVascular Research Foundation, Abbott, Yuhan Corp, CAH-Cordis, Philips, and Infraredx. Several authors reported receiving research grants, consulting fees, and honoraria from various pharmaceutical and healthcare companies, including the funding agencies.